Can you take Iobenguane I 131 with Yohimbe?

The yohimbine in Yohimbe has a moderate potential interaction with Anxiety and Stress.

Yohimbine readily penetrates the blood-brain barrier and may cause anxiety, excitation, and other adverse nervous system effects. Precipitation or exacerbation of psychotic symptoms has been reported. Therapy with yohimbine should be administered cautiously in patients with anxiety, depression, or a history of psychiatric disorders.

The yohimbine in Yohimbe has a moderate potential interaction with Depression.

Yohimbine readily penetrates the blood-brain barrier and may cause anxiety, excitation, and other adverse nervous system effects. Precipitation or exacerbation of psychotic symptoms has been reported. Therapy with yohimbine should be administered cautiously in patients with anxiety, depression, or a history of psychiatric disorders.

The yohimbine in Yohimbe has a major potential interaction with Heart Disease.

Yohimbine can cause hypertension and tachycardia at recommended dosages. Large doses may cause hypotension and cardiac conduction disturbances. Therapy with yohimbine is generally not recommended in patients with hypertension, angina pectoris, or heart disease.

The yohimbine in Yohimbe has a major potential interaction with High Blood Pressure.

Yohimbine can cause hypertension and tachycardia at recommended dosages. Large doses may cause hypotension and cardiac conduction disturbances. Therapy with yohimbine is generally not recommended in patients with hypertension, angina pectoris, or heart disease.

The iobenguane I-131 in iobenguane I 131 has a moderate potential interaction with High Blood Pressure.

Eleven percent of patients who received a therapeutic dose of iobenguane I-131 experienced a worsening of preexisting hypertension defined as an increase in systolic blood pressure to =160 mmHg with an increase of 20 mmHg or an increase in diastolic blood pressure to = 100 mmHg with an increase of 10 mmHg. All changes in blood pressure occurred within the first 24 hours post infusion. Blood pressure should be frequently monitored during the first 24 hours after each therapeutic dose of iobenguane I-131.

The yohimbine in Yohimbe has a major potential interaction with History, Peptic Ulcer.

Yohimbine may increase gastric acid secretion and gastrointestinal motility secondary to its cholinergic activity. Therapy with yohimbine is generally not recommended in patients with a history of peptic ulcer disease.

The yohimbine in Yohimbe has a moderate potential interaction with Liver Disease.

Data are limited concerning the use of yohimbine in patients with liver disease. Yohimbine is thought to undergo metabolism in the liver. Therapy with yohimbine should be administered cautiously in patients with significantly impaired hepatic function.

The yohimbine in Yohimbe has a major potential interaction with Peptic Ulcer.

Yohimbine may increase gastric acid secretion and gastrointestinal motility secondary to its cholinergic activity. Therapy with yohimbine is generally not recommended in patients with a history of peptic ulcer disease.

The yohimbine in Yohimbe has a moderate potential interaction with Psychiatric Disorders.

Yohimbine readily penetrates the blood-brain barrier and may cause anxiety, excitation, and other adverse nervous system effects. Precipitation or exacerbation of psychotic symptoms has been reported. Therapy with yohimbine should be administered cautiously in patients with anxiety, depression, or a history of psychiatric disorders.

The yohimbine in Yohimbe has a moderate potential interaction with Psychosis.

Yohimbine readily penetrates the blood-brain barrier and may cause anxiety, excitation, and other adverse nervous system effects. Precipitation or exacerbation of psychotic symptoms has been reported. Therapy with yohimbine should be administered cautiously in patients with anxiety, depression, or a history of psychiatric disorders.

The yohimbine in Yohimbe has a major potential interaction with Renal Dysfunction.

The use of yohimbine is contraindicated in patients with renal impairment. Yohimbine has mild antidiuretic effects, probably via stimulation of hypothalamic centers and release of posterior pituitary hormone. Agents that reduce or suppress diuresis may aggravate renal diseases.

The iobenguane I-131 in iobenguane I 131 has a moderate potential interaction with Renal Dysfunction.

Renal failure or acute kidney injury and a demonstrated clinically significant decrease in glomerular filtration rate (GFR) has been reported in some patients receiving iobenguane I-131. Monitor renal function during and after treatment with iobenguane I-131. Patients with baseline renal impairment may be at greater risk of toxicity, and their radiation dose may be increased due to the delayed elimination of the drug. Adjust the therapeutic dose based on radiation exposure estimates from the dosimetry assessment. Perform more frequent assessments of renal function in patients with mild or moderate impairment. Iobenguane I-131 has not been studied in patients with severe renal impairment (creatinine clearance <30 mL/min), or end-stage renal disease.

The iobenguane I-131 in iobenguane I 131 has a moderate potential interaction with Underactive Thyroid.

Hypothyroidism was reported in patients who received a therapeutic dose of iobenguane I-131. Caution and close monitoring is advised in patients with history of hypothyroidism. Initiate thyroid- blocking medications starting at least 1 day before and continuing for 10 days after each iobenguane I-131 dose to reduce the risk of hypothyroidism or thyroid neoplasia. Evaluate for clinical evidence of hypothyroidism and measure thyroid-stimulating hormone (TSH) levels prior to initiating treatment with iobenguane I-131 and annually thereafter.